By Journal Record Staff
Courtesy of the Journal Record
OKLAHOMA CITY – Progentec Diagnostics Inc. has completion a second round of funding led by i2E, along with Chicago-based OCA Ventures and NMC Lifesciences, a health care provider.
The funding will help bring Oklahoma City-based Progentec’s tool for identifying lupus flare-ups and a biomarker-based disease-activity index closer to commercialization. Technology created by the Oklahoma Medical Research Foundation is at the core of the platform being developed by Progentec.
Progentec also announced the acquisition of LupusCorner, a patient-empowerment platform for people with systemic lupus erythematosus and lupus nephritis. By integrating LupusCorner’s technology platform and data insights, Progentec plans to develop a lupus-management platform. The founders of LupusCorner, Arif Sorathia and Brett Adelman, have joined Progentec.
Progentec’s technologies include bio-marker based tests to diagnose disease before symptoms begin to show, as well as tests to monitor and predict disease activity levels in Lupus.
“We’ve made tremendous progress in developing a tool for the identification of lupus flare-ups before they occur,” said Mohan Purushothaman, CEO of Progentec. “Today’s funding round is the next step on our journey to making this and other advanced tools commercially available to patients with lupus, a disease that afflicts more than one million Americans, many of whom are women.”
LupusCorner was founded in 2016.